Search

Displaying results 1771 - 1780 of 5759 in total
  1. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.

  2. Drug

    Selisistat

    go.drugbank.com/drugs/DB13978
    Investigational

    Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3

  3. Drug

    Guanosine

    go.drugbank.com/drugs/DB02857
    Investigational

    Guanosine is a nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond.

  4. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    N-alkyl ethylbenzyl dimethyl ammonium (c12-c14) is a quaternary ammonium compound with surfactant properties. … gram-positive and gram-negative antibacterial activities and relatively little chance for systemic absorption and exposure, although the formal mechanism of action of quaternary ammonium compounds like n-alkyl

    Salts: N-alkyl ethylbenzyl dimethyl ammonium chloride (C12-C14)Mixtures: Mevon No. 72 Liq
  5. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.

  6. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    Although there is supportive treatment available for managing Yellow Fever, there are currently no antivirals developed to specifically treat Yellow Fever. … The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease

  7. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    to Efmoroctocog alfa include [DB13999], which is produced by recombinant DNA technology and is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no … To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected

  8. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Dimethylthiambutene

    go.drugbank.com/drugs/DB01444
    ExperimentalIllicit

    Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug. … It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available.

    Synonyms: N,N,1-trimethyl-3,3-di-2-thienylallylamine, N,N-dimethyl-4,4-di(2-thienyl)-3-buten-2-amine
  10. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia